Bio-Techne Corporation (TECH) Stock

Bio-Techne Corporation trades at a P/E ratio of 118.76, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 26.45 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.72 suggests the stock may be undervalued relative to its growth rate.

With a beta of 1.39, Bio-Techne Corporation is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 4.43 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Bio-Techne Corporation achieves a profit margin of 6.02%, meaning it retains $6.02 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 36.30% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 3.68% and ROA at 6.30%, the company achieves moderate returns on invested capital.

Bio-Techne Corporation's revenue grew by 3.60% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 54.80% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Bio-Techne Corporation offers a dividend yield of 0.59%, paying $0.32 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of 8/18/2025.

The dividend sustainability can be assessed through the payout ratio - Bio-Techne Corporation pays $0.32 per share in dividends against earnings of $0.46 per share, resulting in a payout ratio of 69.57%. This high payout ratio of 60-90% leaves limited earnings for reinvestment. While currently sustainable, there's less buffer for dividend growth or protection during earnings downturns. The next dividend payment is scheduled for 8/29/2025.

Bio-Techne Corporation has a market capitalization of $8.50B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 155.55M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.

Bio-Techne Corporation's book value per share is $12.38, while the current stock price is $51.26, resulting in a price-to-book (P/B) ratio of 4.14. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

17 analysts cover TECH with 71% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $65.31 implies 27.4% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:2 Strong Buy, 10 Buy, 5 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.